

IFW

Docket No.: 59 DIV US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Leonard Bell
Serial No.: 10/690,190 Examiner: Unassigned
Filed: October 21, 2003 Group: 3736
For: Method of Prophylaxis Against Large Myocardial Infarctions

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


CERTIFICATE OF MAILING

Date of Deposit: September 15, 2004


I hereby certify that the following:

- ☒ This Certificate of Mailing
- ☒ Information Disclosure Statement
- ☒ PTO-1449 and Cited References
- ☒ Return Receipt Postcard

are being deposited with the United States Postal Service first-class mail on the Date of Deposit indicated above in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.


Rebecca Layman

Mark Farber
C/O
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410



Docket: 59 DIV US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Leonard Bell

Serial No: 10/690,190

Examiner: Unassigned

Filed: October 21, 2003

Group Art Unit: 3736

For: Method of Prophylaxi Against Large Myocardial Infarctions

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's duty of disclosure under 37 C.F.R. §1.56, Applicants submit the enclosed reference for the Examiner's consideration.

It is respectfully requested that the reference(s) submitted with Form PTO-1449 be considered during Examination of the above-identified application and made of record therein. A copy of the reference(s) is/are enclosed. This submission is believed to be in compliance with 37 C.F.R. §1.97 and 37 C.F.R. §1.98.

The citation of the listed item(s) is not a representation that it constitutes a complete or exhaustive listing of prior art or that it constitutes prior art. The item(s) listed is/are submitted in good faith, but is/are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner, it will assist the Examiner in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

() This information disclosure statement is being filed within three (3) months of the filing date of this application.

() This information disclosure statement is being filed within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application.

(x) To the best of Applicant(s) knowledge, this information disclosure statement is being filed before the date of mailing of a first Office Action in connection with this case.

() Enclosed is a certificate under 37 C.F.R. §1.97 (e)(i).

() Enclosed is a petition under 37 C.F.R. §1.97 (d)

() Please charge the petition fee of \$130.00 required under 37 C.F.R. §1.17 (i)(1) to Deposit Account No. 01-0483.

() This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection of Notice of Allowance

() Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97 (e) (1); and no fee is required under 37 C.F.R. §1.17 (p).

() As set forth in 37 C.F.R. §1.97 (c), to the best of Applicant(s) knowledge, this information disclosure statement is being filed before either the mailing of a final action under 37 C.F.R. §1.113 or the mailing of a notice of allowance under 37 C.F.R. §1.113, and is accompanied by the \$220.00 fee as provided for in 37 C.F.R. §1.17(p).

() Please charge the \$240.00 fee required by 37 C.F.R. §1.17(p) to Deposit Account No. 01-0483.

(x) Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or 37 C.F.R. §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 01-0483. Also, in the event any extensions of time for responding are required for the pending application(s), please treat this paper as a petition to extend time as required and charge Deposit Account No. 01-0483 therefor. **TWO COPIES OF THIS SHEET ARE ENCLOSED.**


Early and favorable consideration of the case is respectfully requested.

Dated: September 12, 2007



Mark Farber
Registration No. 34,159
Attorney for Applicants

Mark Farber
C/O
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410
(203) 271-8319



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 59 DIV US	SERIAL NO. 10/690,190
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		
APPLICANT: Leonard Bell		
FILING DATE October 21, 2003		GROUP Art Unit: 3736

U.S. PATENT DOCUMENT

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4 9 8 5 4 5 9	1/15/91	Sunshine et al.			
	5 6 3 5 1 7 8	6/03/97	Sims et al.			
	6 3 5 5 2 4 5	3/12/02	Evans et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	9 5 2 5 5 4 0	9/28/95	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Abdelmegiud et al., "Long-Term Outcome of Transient Uncomplicated In-Laboratory Coronary Artery Closure". Circulation, 1995:91:2733-2741
	Buerke et al., "Novel Small Molecule Inhibitor of C1s Exert Cardioprotective Effects in Ischemia-Reperfusion Injury in Rabbits", Journal of Immunology, 2001: Vol. 6, No. 9: 5375-5380.
	Calliff et al., "Myonecrosis After Revascularization Procedures", J. Amcoll Cardiol, 1998:31: 241-251.
	Fitch et al., "Pharmacology and Biological Efficacy of Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass", Circulation, 1999: Vol. 100, No. 25: 2502-2504.
	Gray et al., "Perioperative Myocardial Infarction: Late Clinical Coarse After Coronary Artery Bypass Surgery", Circulation, 1982: 66:1185-1189.
	Kong et al., "Prognostic Implication of Creatine Kinase Elevation Following Elective Coronary Artery Interventions", JAMA, 1997:277:461-466/
	Menasche, "The Systemic Factor: The Comparative Roles of Cardiopulmonary Bypass and Off-Pump Surgery in the Genesis of Patient Injury During and Following Cardiac Surgery", Annals of Thoracic Surgery, 2001: Vol. 6, No. 72: S2260-S2265,
	Thomas et al., "Inhibition of complement Activity by Humanized anti-C5 Antibody and Single-Chain Fv", Molecular Immunology, 1996, Vol. 33, No. 17/18, 1389-1401.
	Wurzner et al., "Inhibition of Terminal complement Complex formation and Cell Lysis by Monoclonal Antibodies", Complement Inflamm., 8:328-340, 1991.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.